A new CRISPR startup is betting regulators will ease up on gene-editing

Aurora Therapeutics' first target is the rare inherited disease phenylketonuria, also known as PKU. Here at we've been writing about the gene-editing technology CRISPR since 2013, calling it the biggest biotech breakthrough of the century. Yet so far, there's been only one gene-editing drug approved. It's been used commercially on only about 40 patients, all with sickle-cell disease. It's becoming clear that the impact of CRISPR isn't as big as we all hoped. In fact, there's a pall of discouragement over the entire field--with some journalists saying the gene-editing revolution has " lost its mojo ."